
WHO AMR Products Data Analysis

Distributions of product type

Non-traditional : 286 (42.8%)

Antibiotics : 383 (57.2%)




Distributions of R&D phase

Phase I :- 310 (46.3%)

Phase II :- 186 (27.8%)


Phase III :-146 (21.8%)

Preregistration :- 27 (4.04%)




Top Antibacterial Class

Bacteriophage




Top Indication

Gram negative infection



5 Top developers

Qpex GSK



Developers